神经内科重症监护长期使用康格乐:一个病例系列。

IF 0.5

A&A Practice Pub Date : 2023-01-01 DOI:10.1213/XAA.0000000000001652

Olivier Duranteau, Lamine Abdennour, Mehdi Drir, Frederic Clarencon, Corinne Frère, Alice Jacquens, Vincent Degos

{"title":"神经内科重症监护长期使用康格乐:一个病例系列。","authors":"Olivier Duranteau, Lamine Abdennour, Mehdi Drir, Frederic Clarencon, Corinne Frère, Alice Jacquens, Vincent Degos","doi":"10.1213/XAA.0000000000001652","DOIUrl":null,"url":null,"abstract":"Cangrelor is a P2Y12 inhibitor antiplatelet agent, with a rapid onset and offset. The available literature only reviews short-term administration over a few hours. We describe 5 patients who received cangrelor for >1 month in a neurosurgical intensive care unit due to a very high likelihood of requiring emergency revision surgery. Despite multiple therapeutic interruptions for surgical procedures, no hemorrhagic events occurred, and there was only one transient ischemic event, which occurred during transition from cangrelor to ticagrelor. Cangrelor can be a therapeutic option for patients with a high likelihood of requiring revision neurosurgery after intracranial stenting.","PeriodicalId":7307,"journal":{"name":"A&A Practice","volume":"17 1","pages":"e01652"},"PeriodicalIF":0.5000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Long-Term Cangrelor Administration in Neurology Intensive Care: A Case Series.\",\"authors\":\"Olivier Duranteau, Lamine Abdennour, Mehdi Drir, Frederic Clarencon, Corinne Frère, Alice Jacquens, Vincent Degos\",\"doi\":\"10.1213/XAA.0000000000001652\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Cangrelor is a P2Y12 inhibitor antiplatelet agent, with a rapid onset and offset. The available literature only reviews short-term administration over a few hours. We describe 5 patients who received cangrelor for >1 month in a neurosurgical intensive care unit due to a very high likelihood of requiring emergency revision surgery. Despite multiple therapeutic interruptions for surgical procedures, no hemorrhagic events occurred, and there was only one transient ischemic event, which occurred during transition from cangrelor to ticagrelor. Cangrelor can be a therapeutic option for patients with a high likelihood of requiring revision neurosurgery after intracranial stenting.\",\"PeriodicalId\":7307,\"journal\":{\"name\":\"A&A Practice\",\"volume\":\"17 1\",\"pages\":\"e01652\"},\"PeriodicalIF\":0.5000,\"publicationDate\":\"2023-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"A&A Practice\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1213/XAA.0000000000001652\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"A&A Practice","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1213/XAA.0000000000001652","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

Cangrelor是一种P2Y12抑制剂抗血小板药物，具有快速起效和抵消作用。现有文献仅回顾了几个小时内的短期用药。我们描述了5例因极有可能需要紧急翻修手术而在神经外科重症监护病房接受康瑞洛治疗超过1个月的患者。尽管手术过程中多次中断治疗，但没有发生出血事件，只有一次短暂性脑缺血事件发生在从康格瑞洛到替格瑞洛的过渡过程中。对于颅内支架植入术后极有可能需要翻修神经外科手术的患者，angrelor可作为一种治疗选择。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Long-Term Cangrelor Administration in Neurology Intensive Care: A Case Series.

Cangrelor is a P2Y12 inhibitor antiplatelet agent, with a rapid onset and offset. The available literature only reviews short-term administration over a few hours. We describe 5 patients who received cangrelor for >1 month in a neurosurgical intensive care unit due to a very high likelihood of requiring emergency revision surgery. Despite multiple therapeutic interruptions for surgical procedures, no hemorrhagic events occurred, and there was only one transient ischemic event, which occurred during transition from cangrelor to ticagrelor. Cangrelor can be a therapeutic option for patients with a high likelihood of requiring revision neurosurgery after intracranial stenting.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

A&A Practice ANESTHESIOLOGY-

自引率

0.00%

发文量

期刊介绍： A & A Case Reports, our new online journal publishing Case Reports, related Editorial Commentary, and Correspondence. Anesthesia & Analgesia 1 and Anesthesiology 2 recently announced that they were suspending publication of Case Reports. One reason is that Case Reports typically reduce the Impact Factor of a journal because they are rarely cited. Regardless of the merits of Impact Factor as a metric of journal worth, journals and their editors necessarily consider Impact Factor in strategic planning. At the same time, Case Reports are appreciated by readers for describing “real life” management of difficult or unusual cases not often encountered by practitioners. In a recent issue of Anesthesia & Analgesia, Steven Shafer1 identified many Case Reports whose publication launched productive careers dedicated to solving the puzzle posed by an unusual observation in a single patient.